Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 3/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.37 |
| ▸ | TACR2 | P21452 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SHBG | P04278 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2181329 | 0.91 | HRH3 (0.42) | TDP1MAOBALDH1A1HSD17B10MEN1 | |
| SCHEMBL2177163 | 0.90 | THRA (0.47) | TDP1HTR2AMAOBTHRATHRB | |
| SCHEMBL80599 | 0.89 | TAAR1 (0.54) | TDP1HTR2ATAAR1SIGMAR1 | |
| SCHEMBL9673289 | 0.88 | THRA (0.50) | TDP1HTR2AMAOBTHRATHRB | |
| SCHEMBL9670792 | 0.88 | THRA (0.50) | TDP1HTR2AMAOBTHRATHRB | |
| SCHEMBL9673266 | 0.88 | THRA (0.50) | TDP1HTR2AMAOBTHRATHRB | |
| SCHEMBL9670640 | 0.88 | THRA (0.50) | TDP1HTR2AMAOBTHRATHRB | |
| SCHEMBL7560719 | 0.87 | SIGMAR1 (0.40) | TDP1CYP3A4SIGMAR1 | |
| SCHEMBL8062210 | 0.87 | LPL (0.46) | HTR2ATHRATHRBESR1ADRA2A | |
| SCHEMBL8072360 | 0.87 | CA2 (0.54) | HTR2ATHRATHRBESR1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367149-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-12252467-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2025-03-18 | — | — | US | disclosed |
| US-12180151-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-20240417363-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2024-12-19 | — | — | US | disclosed |
| EP-4464688-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS USEFUL FOR THE PREVENTION OR TREATMENT OF DISEASE | Espervita Therapeutics, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118903087-A | Functionalized long chain hydrocarbon mono-and dicarboxylic acids useful in the prevention or treatment of disease | 埃斯佩尔维塔治疗股份有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-114126593-B | Functionalized long chain hydrocarbon mono-and dicarboxylic acids useful in the prevention or treatment of disease | 埃斯佩尔维塔治疗股份有限公司 | 2024-07-26 | — | — | CN | disclosed |
| EP-4003314-B1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS USEFUL FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS INC (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-4003314-B1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS USEFUL FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS INC (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20240092721-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | US | disclosed |
| EP-4003314-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS USEFUL FOR THE PREVENTION OR TREATMENT OF DISEASE | Espervita Therapeutics, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11267778-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| US-11084773-B1 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20210221765-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2021-07-22 | — | — | US | disclosed |
| WO-2021021563-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS USEFUL FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| US-20210024447-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2021-01-28 | — | — | US | disclosed |
| US-5093370-A | Useful prior to insertion of tracheotomy tube or discission | TOBISHI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 1992-03-03 | — | — | US | disclosed |
| EP-0185080-B1 | ALPHA-, OMEGA-DICARBOXYLIC ACIDS, PROCESS FOR THEIR PREPARATION AND MEDICINES COMPOSED THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1989-11-08 | — | — | EP | disclosed |
| US-4711896-A | ANTIDIABETIC, ANTILIPEMIC AGENTS | EPIS S.A. (CH) | 1987-12-08 | — | — | US | disclosed |
| US-4689344-A | ANTICHOLESTEROL AGENTS | EPIS S.A. (CH) | 1987-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11267778-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease | CPT1A, PPARG, PC | TDP1 4830/4885HTR2A 3855/4885MAOB 3029/4885 |
| US-20210221765-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | CPT1A, PPARG, PC | TDP1 4830/4885HTR2A 3855/4885MAOB 3029/4885 |
| US-20250367149-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | CPT1A, PPARG, PC | TDP1 4830/4885HTR2A 3855/4885MAOB 3029/4885 |
| US-11084773-B1 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease | CPT1A, PPARG, PC | TDP1 4830/4885HTR2A 3855/4885MAOB 3029/4885 |
| US-20240092721-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | CPT1A, PPARG, PC | TDP1 4830/4885HTR2A 3855/4885MAOB 3029/4885 |
| US-20210024447-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | CPT1A, PPARG, PC | TDP1 4830/4885HTR2A 3855/4885MAOB 3029/4885 |
| US-12252467-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease | CPT1A, PPARG, PC | TDP1 4830/4885HTR2A 3855/4885MAOB 3029/4885 |
| US-12180151-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease | CPT1A, PPARG, PC | TDP1 4830/4885HTR2A 3855/4885MAOB 3029/4885 |
| US-20240417363-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | CPT1A, PPARG, PC | TDP1 4830/4885HTR2A 3855/4885MAOB 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.